US firm NephroGenex, which conducted its initial public offering early this year, saw its share price close up almost 300% at $13.35 on 31 December on news that its sole drug candidate, Pyridorin, was found to be safe in a cardiac safety study.
The IPO in February was priced at $12 a share, but the Raleigh, NC-company had seen its stock price drift...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?